Summit Expands Ivonescimab Phase III in Colorectal Cancer
October 17, 2025
Summit Therapeutics Inc. announced the expansion of its Phase III clinical development program of the novel, potential first-in-class investigational bispecific antibody, ivonescimab, into colorectal cancer